Melian Agustin's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Sep 20, 2021
- Accession no.
- 0000899243-21-036577
- Filed
- Sep 20, 2021
- Trade date
- Apr 5-Sep 17, 2021
- Filing delay
- 168 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $896.7K. It was filed 168 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Melian AgustinCIK 0001818064 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2021 | Common Stock | SSaleDisposed | −18,212 | $23.89 | −$435,084.68 | 498,304 | Direct | |
| Jul 2, 2021 | Common Stock | SSaleDisposed | −18,586 | $19.99 | −$371,534.14 | 479,718 | Direct | |
| Sep 15, 2021 | Common Stock | SSaleDisposed | −800 | $24.03F3 | −$19,224 | 478,918 | Direct | |
| Sep 17, 2021 | Common Stock | SSaleDisposed | −2,950 | $24.01F3 | −$70,829.5 | 475,968 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 2 transactions in Table I.